CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
Clinical Trials
18
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
11
61.1%
Terminated
4
22.2%
Unknown
1
5.6%
Withdrawn
2
11.1%
No approval data available
- The EPO Boards of Appeal revoked EP 3 590 949, a Moderna mRNA vaccine patent that had been upheld at first instance. - Board of Appeal 3.3.08 issued the decision after a two-day oral hearing, with added matter cited as a likely factor. - The ruling removes patent grounds Moderna had used against BioNTech and Pfizer, though divisional applications and further litigation remain.
- GSK's infringement claims over mRNA delivery patent EP 2 590 626 will be heard at The Hague Local Division of the Unified Patent Court on 1 and 3 September, targeting Moderna, BioNTech and Pfizer. - The dispute stems from GSK's decision to enforce its mRNA patent portfolio against the manufacturers of the successful Covid-19 vaccines, with parallel litigation also underway in the US, Ireland and the UK. - The Hague has emerged as the leading UPC venue for pharmaceutical patent litigation, handling roughly a quarter of all such cases despite accounting for only about 12% of overall filings. - A prior CureVac–BioNTech–Pfizer settlement, involving a $370 million payment and 1% royalty to GSK, expressly reserved GSK's own patent enforcement rights against Pfizer and BioNTech.
- Moderna has filed a countersuit against CureVac in the ongoing legal battle over mRNA COVID-19 vaccine technology patents. - Sanofi has separately filed suit against both Pfizer and Moderna, alleging their COVID-19 vaccines infringe on Sanofi's mRNA technology patents. - The multi-front litigation highlights the intensifying intellectual property disputes surrounding foundational mRNA vaccine platform technologies. - These legal outcomes could have significant implications for future mRNA-based therapeutic development and royalty structures across the pharmaceutical industry.
- A U.S. federal judge dismissed Acuitas Therapeutics' lawsuit seeking to clear Pfizer-BioNTech's Comirnaty COVID-19 vaccine of GSK patent allegations, giving GSK a procedural win in the ongoing mRNA technology dispute. - The ruling maintains focus on the main Delaware litigation between GSK and the vaccine makers, where GSK alleges Comirnaty infringes patents for mRNA vaccine technology developed over a decade before the pandemic. - GSK previously secured $370 million upfront plus 1% royalties from a separate mRNA patent settlement with CureVac and the same vaccine manufacturers in August 2025. - The dismissal does not resolve the core patent infringement claims or determine whether GSK's patents are valid, leaving the fundamental dispute between the companies unresolved.
- Mana.bio appointed three strategic leaders including Thaminda Ramanayake as board member, bringing over 20 years of biopharmaceutical experience from CureVac and other major companies. - The company will present breakthrough data at ASGCT 2026 demonstrating machine learning-driven lipid nanoparticle design for in vivo T-cell engineering applications. - Lead LNP candidates showed successful in vivo T-cell delivery in non-human primates and achieved near complete B-cell tumor clearance in mouse models. - The AI platform leverages the world's largest curated LNP dataset to predict safety, efficacy, and stability for next-generation genetic medicines.
- BioNTech successfully secured 81.74% of CureVac shares by the December 3, 2025 deadline, surpassing the critical 80% threshold needed to complete the acquisition. - The acquisition provides BioNTech access to CureVac's valuable patent portfolio and research capabilities, supporting its strategic evolution from COVID-19 vaccine producer to oncology specialist. - Analysts from Jefferies and Berenberg maintain buy ratings with price targets of $150-151 per ADS, suggesting over 50% upside potential if integration synergies are realized. - A subsequent offering period remains open until December 18, 2025, allowing remaining CureVac shareholders to exchange their holdings under the same terms.
- UbiVac's DPV-001 cancer vaccine demonstrated a 3x improvement in response rates and progression-free survival compared to standard-of-care immunotherapy in head and neck squamous cell carcinoma patients. - The "off-the-shelf" immunotherapy contains over 400 Dark Matter-derived antigens designed to target virtually all solid tumors, with more than 34 patients treated to date. - Clinical data showed a 2x improvement in overall survival, 56% response rate in PD-1-naïve patients versus 19% standard-of-care, and 33% response rate in patients who previously failed anti-PD-1 therapy. - UbiVac plans to initiate a Phase II trial targeting the difficult-to-treat population of patients who failed prior anti-PD-1 therapy, representing a key value inflection point for the company.
- CureVac achieved a dramatic financial turnaround with €371.6 million net income in Q3 2024, reversing from a €54 million operating loss in the same period last year. - The German mRNA company received €400 million upfront from GSK in a restructured partnership that transferred control of COVID-19 and influenza vaccine programs to the British pharmaceutical giant. - CureVac is implementing a 30% workforce reduction and refocusing on oncology, with early clinical data showing antigen-specific T-cell responses in 77% of glioblastoma patients treated with its CVGBM cancer vaccine. - The company's strengthened cash position of €551 million extends its financial runway to 2028, eliminating immediate capital raising requirements.
- Germany's Federal Cartel Office granted unconditional approval for BioNTech's $1.25 billion acquisition of CureVac, removing the final regulatory obstacle for the deal. - The acquisition aims to strengthen BioNTech's oncology strategy by combining mRNA-based cancer immunotherapy technologies and manufacturing capabilities. - Competition authorities found no significant overlaps between the companies' research pipelines and determined the merger would not restrict innovation-based competition. - The all-stock transaction provides CureVac shareholders with approximately $5.46 per share, representing a 55% premium over the three-month average price.
- GSK will receive $370 million upfront from CureVac following a patent settlement involving BioNTech and Pfizer over mRNA vaccine technology, with $320 million paid in cash. - The pharmaceutical giant will collect 1% royalties on US sales of Pfizer-BioNTech's influenza, COVID-19, and combination mRNA vaccines starting in 2025. - The settlement includes significant reductions in royalties GSK must pay on its own future mRNA vaccine products and potential additional payments of $130 million if BioNTech's acquisition of CureVac closes. - CureVac and its partners will receive a total of $740 million from the broader patent dispute resolution with Pfizer and BioNTech over mRNA COVID-19 vaccine technology.
